In HER2+ breast cancer, the prognostic effect was evident in both HER2+/HR+ and HER2+/HR− subgroups and was apparent regardless of the administration of adjuvant trastuzumab, whereas among the HER2− cases, the CD163+ TAM count was not significantly associated with survival. The gene discussed is ERBB2; the disease is breast carcinoma.